Cargando…

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study

Long-acting antipsychotic injections require that psychiatric nurses choose the proper injection site and technique to avoid harming patients. This research conducted a mixed-method study to examine the long-acting injectable antipsychotic (LAI) knowledge, practice, and administrative barriers in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yao-Yu, Hou, Wen-Li, Lin, Mei-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298424/ https://www.ncbi.nlm.nih.gov/pubmed/37372788 http://dx.doi.org/10.3390/healthcare11121670

Ejemplares similares

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
por: Miron, Ana A., et al.
Publicado: (2022)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
por: McKee, Kyle A., et al.
Publicado: (2021)

Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006–2021
por: Lin, Ta-Chun, et al.
Publicado: (2023)

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives
Publicado: (2022)

An 8-year longitudinal study of long-acting injectable (LAI) antipsychotics. Prescription trends and therapeutic drug monitoring to inform precision dosing
por: Piacentino, D., et al.
Publicado: (2022)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
por: Ortega-Hernández, G., et al.
Publicado: (2023)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
por: Haider, Batool, et al.
Publicado: (2023)

Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis
por: Prajapati, Asta R, et al.
Publicado: (2016)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Lais /
por: France, Marie de
Publicado: (1994)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting
por: Alastanos, Jennifer N., et al.
Publicado: (2019)

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA
por: Garcia-Carmona, Juan-Antonio
Publicado: (2018)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

PM499. Improvement of cognitive function before and after 2-year treatment with long-acting injection (LAI) of antipsychotics evaluated by NIRS using single word-induced hemoglobin variation as an index
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services
por: Paton, Carol, et al.
Publicado: (2021)

Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics
por: Carr, Chelsea N., et al.
Publicado: (2016)

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
por: Reymann, Stephan, et al.
Publicado: (2022)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
por: Chiu, Lin-Ling, et al.
Publicado: (2019)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services
por: Hsu, Hsiao-Fen, et al.
Publicado: (2019)

Estimating Leaf Area Index (LAI) in Vineyards Using the PocketLAI Smart-App
por: Orlando, Francesca, et al.
Publicado: (2016)

Therapeutic drug monitoring of LAI antipsychotics as a predictor of clinical relapse: a one-year follow-up
por: D’Anna, G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9msn94kg3ahajrdrvn18io4b0q